Continuous venovenous hemodialysis may be effective in digoxin removal in digoxin toxicity: A case report.
Cenk GokalpAysun Fatma DoganGuray AygunIlhan KurultakSedat UstundagPublished in: Hemodialysis international. International Symposium on Home Hemodialysis (2020)
Digoxin is a cardiac glycoside that is used for the treatment of heart failure and atrial fibrillation. Besides its careful close follow-up, toxicity affects nearly 1% of congestive heart failure patients. Cessation of the drug, appropriate electrolyte and rhythm control and digoxin-Fab antibody are the mainstay for toxicity treatment in these patients. As known, hemodialysis and peritoneal dialysis are not effective by the means of digoxin removal. We present a 66-year-old patient who admitted to hospital with digoxin toxicity and severe acute kidney injury. The patient was treated with continuous venovenous hemodialysis because of her hypervolemia, hyperkalemia, cardiac instability, and the thought of probable decrease in digoxin levels concerning the continuous nature of solute clearance. Without the treatment using digoxin-specific Fab antibodies, the patient's digoxin level was decreased successfully with continuous venovenous hemodialysis. In conclusion, continuous venovenous hemodialysis may be a treatment option in digoxin toxicity especially those who suffer from severe renal dysfunction and cannot access digoxin antidote.
Keyphrases
- end stage renal disease
- peritoneal dialysis
- chronic kidney disease
- heart failure
- atrial fibrillation
- extracorporeal membrane oxygenation
- oxidative stress
- acute kidney injury
- healthcare
- ejection fraction
- case report
- coronary artery disease
- left ventricular
- cardiac surgery
- early onset
- combination therapy
- heart rate
- electronic health record